PCOS and Hair Thinning: What the 2023 Guideline Says

Hair thinning is one of the reasons women with polycystic ovary syndrome look for help, and it is one of the few areas of this site where a formal, international clinical guideline says something specific. The 2023 International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome — published across several endocrinology journals in 2023 — deals with hair loss directly, and its wording is worth reading before any product page is opened.

What the guideline says about hair loss

Three things, and each is more careful than the internet's version.

On what hair loss tells you. The guideline states that female pattern hair loss and acne in isolation, without hirsutism, are relatively weak predictors of biochemical hyperandrogenism. In other words, thinning hair on its own is not strong evidence that androgens are the driver — which is a caution against assuming that your hair loss is "the PCOS" and treating it as such.

On anti-androgens for hair loss. The guideline indicates that anti-androgens could be trialled for female pattern hair loss when used alongside a combined oral contraceptive pill, while acknowledging the lack of evidence in the PCOS population specifically. It cites the negative psychological impact of female pattern hair loss as the reason to consider it despite that thin evidence — a candid piece of reasoning that tells you the strength of the recommendation as well as its direction.

On contraception. This is the non-negotiable part. The guideline says women and adolescents taking anti-androgens should be strongly counselled to use effective contraception, because of the risk of under-virilisation of a male fetus. Any route that involves an anti-androgen — spironolactone among them — carries that requirement with it.

The certainty ratings attached to the anti-androgen recommendations in the guideline are the lowest the framework has. That is the honest context for a decision, and it is the opposite of how these medicines are described in the places that sell access to them.

Why hair loss in PCOS is not one problem

PCOS is a metabolic and endocrine condition, and several of the things that travel with it can affect hair independently of androgens: rapid weight change, iron status, thyroid disease and the psychological load of the condition itself. A 2022 review in Reproductive Sciences on PCOS and depression notes how much of the loss of self-esteem in PCOS is attributed to the visible features — androgenic alopecia and hirsutism among them — and how much more common depression is in this group than in the general population.

That matters practically, because it means two women with PCOS and thinning hair may need different things: one an endocrine conversation, one an iron test, one a dermatology referral, and often more than one at once. It also means that being told "it's just your PCOS, nothing to do" is not good enough.

What to ask for at the appointment

You are not diagnosing yourself, and you are not ordering your own tests. But the following are all reasonable to raise, and all of them are free to say:

• whether the hair loss is pattern loss, a shedding phase, or both — the exam and the hair-pull test the dermatologists describe take minutes
• whether bloods are worth doing in your case, including iron studies and thyroid function, and what the results would change
• if an anti-androgen is proposed, what contraception is required alongside it, and for how long
• what the plan is if nothing changes in six months — because six months is the horizon on which hair treatments are judged

Where hair treatment for PCOS overlaps with everything else

There is no PCOS-specific hair treatment. Once a clinician has decided what is driving the loss, the options are the same ones open to any woman, and the evidence behind them is the same evidence: topical minoxidil with randomised trials in women, anti-androgens with mixed trials and case series, devices and supplements below that. Every hair-loss treatment for women, graded by what was tested in women sets out each route with its evidence, its price and its cautions.

Two things are worth carrying across from this article when you read that page. The first is the contraception requirement, which changes which routes are even available to you. The second is the guideline's own scepticism: it recommends trying anti-androgens for hair loss while saying the evidence in PCOS is lacking. Both can be true, and you are allowed to weigh them yourself.

Spironolactone, in the numbers that exist

Because spironolactone is the anti-androgen most often raised, here is the best summary evidence available, from a 2023 systematic review and meta-analysis of its use in female pattern hair loss: improvement reported in 56.6% of patients overall, 65.8% where it was combined with another treatment and 43.2% as monotherapy, with no improvement or only modest improvement in 37.8%. Adverse effects reported in at least two studies were scalp itching or increased scurf (18.9%), menstrual disturbance (11.9%) and facial hypertrichosis (6.9%), with 2.8% discontinuing.

Those are not trial-grade numbers from a single clean study — the review itself flags significant heterogeneity — and this site prints no dose, no schedule and no monitoring plan. That is prescriber territory, and the point of quoting the figures is so you can ask a better question rather than accept a better pitch.

The supplements question, specifically for PCOS

Supplements marketed for hair are not regulated as treatments and are not approved to treat hair loss. Where a supplement contains botanicals with hormonal claims, the PCOS context makes "check with a doctor first" more than a formality — you may be taking a combined pill, metformin or an anti-androgen, and interactions are a clinical matter.

If you want to see how the best-evidenced brand in that category actually scores when the funding and the study design are read, our evidence-graded review of the Nutrafol women's range shows the arithmetic. It is a 6 out of 10 on a published scale — and the marks it loses are the marks that matter for anyone managing a medical condition.

The short version

PCOS and hair loss belong together in an appointment, not in a checkout. The guideline written by the people who manage the condition is cautious about anti-androgens for hair, insistent about contraception alongside them, and unromantic about what thinning hair on its own proves. None of those three positions will be found on a page trying to sell you something, and all three change what you should do next.

If your thinning is a widening part rather than diffuse shedding, why a part widens covers the pattern, the imitators and what the examination looks like.